Home Tools
Log in
Cart

Search Result

Search Results for " ldlr "

12

Compounds

Cat No. Product Name Synonyms Targets
T9920 Evolocumab Others
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
T9276 SBC-115337 Others , Serine/threonin kinase
SBC-115337 is a PCSK9 inhibitor.
T67776 PCSK9-IN-11 Others
PCSK9-IN-11 (compound 5r) is a potent PCSK9 inhibitor with oral activity. PCSK9-IN-11 shows inhibitory activity of PCSK9 transcription in HepG2 cells (IC50= 5.7 μM). PCSK9-IN-11 can increase LDL receptor (LDLR) protein l...
T72025 PCSK9-IN-10 Serine/threonin kinase
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Li...
T5S0053 Coptisine Coptisin Indoleamine 2,3-Dioxygenase (IDO)
1. Coptisine (Coptisin) treatment increases cell viability based on its reversal effect on the enhanced activity of Indoleamine 2, 3-dioxygenase . 2. Coptisine treats myocardial I/R likely through suppressing myocardial ...
T74577 Milpocitide
Milpocitide, a (293-333)-peptide fragment of the human low-density lipoprotein receptor (LDLR), specifically corresponds to the EGF-like domain 1 [1].
T15561 Imanixil HOE-402(free base) Others
Imanixil is an inducer of the LDL receptor (LDLR) and it is also a potent cholesterol-lowering compound. It also inhibits very low density-lipoprotein (VLDL) production and consequently decreases atherosclerosis developm...
T81535 PCSK9-IN-20
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor exhibiting an IC50 value of 3.96 µM, shown to reduce PCSK9 and enhance LDLR protein levels in vitro [1].
T39528 PCSK9-IN-2 PCSK9-IN-2
PCSK9-IN-2 is a newly developed small molecule that effectively inhibits the protein-protein interaction (PPI) between PCSK9 and LDLR. It has been found to have a potent inhibitory activity with an IC50 value of 7.57 μM.
T77014 Frovocimab
Frovocimab (LY 3015014), a humanized IgG4 monoclonal antibody (mAb), acts by neutralizing PCSK9. This mechanism effectively prevents PCSK9 from binding to the LDL receptor (LDLR) while allowing for the normal proteolytic...
T78718 Dim16
Dim16, a dual inhibitor of PCSK9/HMG-CoAR, demonstrates potent activity with an IC50 of 19 nM against PCSK9 and significantly impedes PCSK9-LDLR interaction with an IC50 of 0.8 nM, leading to an enhanced LDL uptake in He...
T78806 PPARδ agonist 9 PPAR
PPARδ agonist 9 (compound 21), with an EC50 of 3.6 nM, is effective in vivo, decreasing serum MCP-1 concentrations in mice and markedly reducing atherosclerotic development in the LDLr-KO model with an inhibition rate of...
TargetMol